How Naturalistic Driving Compares to Aβ‐related CSF and Plasma Biomarkers in the Detection of Amyloid PET Positivity: A Machine Learning Approach

Identifying individuals with Alzheimer disease (AD) pathology a decade or more before the onset of dementia symptoms can be achieved with amyloid positron emission tomography (PET), cerebrospinal fluid (CSF) biomarkers, or blood biomarkers. This study compares driving behavior with CSF and blood biomarkers to identify amyloid deposition in AD, as defined by the “gold standard” PET‐amyloid.